Myasthenia Gravis - Pipeline Review, H1 2020

January 2020 | 207 pages | ID: ME48430D872EN
Global Markets Direct

Abstracts

Myasthenia Gravis - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myasthenia Gravis - Pipeline Review, H1 2020, provides an overview of the Myasthenia Gravis (Immunology) pipeline landscape.

Myasthenia gravis is autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia and difficulty swallowing, chewing and speaking. Treatment includes immunosuppressants, corticosteroids and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myasthenia Gravis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Myasthenia Gravis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myasthenia Gravis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 7, 8, 7, 16 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Myasthenia Gravis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Myasthenia Gravis (Immunology).
• The pipeline guide reviews pipeline therapeutics for Myasthenia Gravis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Myasthenia Gravis (Immunology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Myasthenia Gravis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Myasthenia Gravis (Immunology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Myasthenia Gravis (Immunology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Myasthenia Gravis (Immunology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Myasthenia Gravis - Overview
Myasthenia Gravis - Therapeutics Development
Myasthenia Gravis - Therapeutics Assessment
Myasthenia Gravis - Companies Involved in Therapeutics Development
Myasthenia Gravis - Drug Profiles
Myasthenia Gravis - Dormant Projects
Myasthenia Gravis - Discontinued Products
Myasthenia Gravis - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Myasthenia Gravis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Myasthenia Gravis - Pipeline by Ahead Therapeutics SL, H1 2020
Myasthenia Gravis - Pipeline by Akari Therapeutics Plc, H1 2020
Myasthenia Gravis - Pipeline by Alexion Pharmaceuticals Inc, H1 2020
Myasthenia Gravis - Pipeline by Alpha Cancer Technologies Inc, H1 2020
Myasthenia Gravis - Pipeline by Amneal Pharmaceuticals Inc, H1 2020
Myasthenia Gravis - Pipeline by AnTolRx Inc, H1 2020
Myasthenia Gravis - Pipeline by Argenx SE, H1 2020
Myasthenia Gravis - Pipeline by BioMarin Pharmaceutical Inc, H1 2020
Myasthenia Gravis - Pipeline by Bristol-Myers Squibb Co, H1 2020
Myasthenia Gravis - Pipeline by Cabaletta Bio Inc, H1 2020
Myasthenia Gravis - Pipeline by Cartesian Therapeutics Inc, H1 2020
Myasthenia Gravis - Pipeline by CuraVac Inc, H1 2020
Myasthenia Gravis - Pipeline by DAS Therapeutics Inc, H1 2020
Myasthenia Gravis - Pipeline by Grifols SA, H1 2020
Myasthenia Gravis - Pipeline by HanAll Biopharma Co Ltd, H1 2020
Myasthenia Gravis - Pipeline by Hibernaid Inc, H1 2020
Myasthenia Gravis - Pipeline by KIMS Pharmaceutical Co Ltd, H1 2020
Myasthenia Gravis - Pipeline by Kiniksa Pharmaceuticals Corp, H1 2020
Myasthenia Gravis - Pipeline by Millennium Pharmaceuticals Inc, H1 2020
Myasthenia Gravis - Pipeline by Momenta Pharmaceuticals Inc, H1 2020
Myasthenia Gravis - Pipeline by Neurotune AG, H1 2020
Myasthenia Gravis - Pipeline by Nihon Pharmaceuticals Co Ltd, H1 2020
Myasthenia Gravis - Pipeline by Novartis AG, H1 2020
Myasthenia Gravis - Pipeline by Pfizer Inc, H1 2020
Myasthenia Gravis - Pipeline by Protalex Inc, H1 2020
Myasthenia Gravis - Pipeline by Ra Pharmaceuticals Inc, H1 2020
Myasthenia Gravis - Pipeline by RemeGen Ltd, H1 2020
Myasthenia Gravis - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Myasthenia Gravis - Pipeline by Toleranzia AB, H1 2020
Myasthenia Gravis - Pipeline by Tolerion Inc, H1 2020
Myasthenia Gravis - Pipeline by UCB SA, H1 2020
Myasthenia Gravis - Pipeline by Viela Bio Inc, H1 2020
Myasthenia Gravis - Dormant Projects, H1 2020
Myasthenia Gravis - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Myasthenia Gravis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Ahead Therapeutics SL
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Alpha Cancer Technologies Inc
Amneal Pharmaceuticals Inc
AnTolRx Inc
Argenx SE
BioMarin Pharmaceutical Inc
Bristol-Myers Squibb Co
Cabaletta Bio Inc
Cartesian Therapeutics Inc
CuraVac Inc
DAS Therapeutics Inc
Grifols SA
HanAll Biopharma Co Ltd
Hibernaid Inc
KIMS Pharmaceutical Co Ltd
Kiniksa Pharmaceuticals Corp
Millennium Pharmaceuticals Inc
Momenta Pharmaceuticals Inc
Neurotune AG
Nihon Pharmaceuticals Co Ltd
Novartis AG
Pfizer Inc
Protalex Inc
Ra Pharmaceuticals Inc
RemeGen Ltd
Takeda Pharmaceutical Co Ltd
Toleranzia AB
Tolerion Inc
UCB SA
Viela Bio Inc